Orexo Ab · OMXSTO:ORX
Orexo Ab — Shareholder Meeting (April 2018)
14 slides from Orexo Ab's shareholder meeting presentation, Apr 12, 2018
Slide 1: Fighting opioid dependence from a strong platform
Fighting opioid dependence from a strong platform Annual General Meeting April 12, 2018 Nasdaq Stockholm: ORX US OTC Market: ORXOY (ADR)
Slide 2: Legal Disclaimer
Legal Disclaimer • This presentation, which is personal to the recipient, has been prepared and produced by Orexo AB (publ) (“Orexo”) solely for the benefit of investment analysis and may not be used for any purpose other than assessment of investments concerning Orexo. Unless otherwise stated, Orex
Slide 3: Orexo with a range of compelling value drivers and solid foundation
Orexo with a range of compelling value drivers and solid foundation to take Orexo to the next level 1 Fully integrated specialty pharma company focused on growing Strong EBITDA and addiction market Established 6 cash flow commercial 2 generating capacity platform in the US as the operating with a fi
Slide 4: Orexo leaving 2017 with strengthened financials and positive results
Orexo leaving 2017 with strengthened financials and positive results 2017 Net Revenue: SEKM 644 ”Attractive net revenue stream from launched products and partner projects” 2017 EBITDA: ”Profitable company since 2016” SEKM 78 2017 Cash flow from operations: SEKM 147 ”>300 M in positive cash flow 2016
Slide 5: 2016 marked a turning point when Orexo became profitable
2016 marked a turning point when Orexo became profitable Revenue SEKM EBITDA SEKM 700 100 Future profitability growth will be driven 600 80 by revenue growth from Zubsolv® and 60 reduced COGS 500 40 New Market Access 400 20 agreements in place from Jan. 1 300 0 2018 driving 2013 2014 2015 2016 201
Slide 6: Strong re-bound in Zubsolv tablet volume in 2018
Strong re-bound in Zubsolv® tablet volume in 2018 Zubsolv Tablet Volume (rolling 4 weeks) Average weekly sales 400 000 Maryland FFS Open Humana, Envision Maryland FFS excl Exclusive 350 000 300 000 250 000 CVS Caremark SelfRefind/ WellCare UHG exit ACA Tablets 200 000 WellCare contract 150 000 100 0
Slide 7: No indication the market will shrink with the opioid crisis continuing to escalate
No indication the market will shrink with the opioid crisis continuing to escalate in the US Large and growing need for opioid rescue medication Alarming number of opioid related Negative trend continues according to CDC overdoses leading to >50,000 deaths in US surveillance data (Increases in opioi
Slide 8: R&D and business development focused on helping patients suffering from addiction
R&D and business development focused on helping patients suffering from addiction From prevention to treatment Treatment of addiction e.g. Zubsolv® and OX382 Prevention of addiction Treatment of symptoms and co-morbidities Orexo internal development focused on optimizing drug delivery of known APIs
Slide 9: The development strategy follows a 3 pronged approach
The development strategy follows a 3 pronged approach Products & Asset classes Description Projects Strategy • Development projects aimed at • Zubsolv® US Internal Products inside broadening our commercial platform development • OX382 our commercial (complemented by • Providing a comprehensive range
Slide 10: Expanding profitability and commercial abilities
Looking ahead, the focus is to use the positive cash flow from Zubsolv® to grow the business from a broader portfolio Orexo’s evolution from a loss making R&D company to a profitable specialty pharma company Key drivers of growth 1 Maximise Zubsolv’s potential in a globally fast growing market Expan
Slide 11: Zubsolv with patent protection until 2032 in the US
Zubsolv® with patent protection until 2032 in the US Two ongoing patent litigations against Actavis Comprehensive patent protection in Ongoing patent litigations against Actavis Orange book until September 2032 • US district court have affirmed validity and 1. Patent No. Expiration infringement of ‘
Slide 12: A focus in 2017 has been to ensure we follow the UN Global Compact
A focus in 2017 has been to ensure we follow and support the principles of the UN Global Compact Human Labor Rights Anti- More insights in Environment Corruption our Sustainability Report Strengthen the prevention and treatment of substance abuse, including narcotic drug abuse and harmful use of alc
Slide 13: Strong platform and exciting opportunities for 2018
Strong platform and exciting opportunities for 2018 Core business at the heart of the biggest health problem in the US - ever Strong financial performance and position with full year positive EBIT and secured long term financing A pipeline of interesting internal projects that will progress fu
Slide 14: THANKS
THANKS For more information please visit www.orexo.com. You can IR Contact: Lena Wange, IR & Communications Manager also follow Orexo at Twitter @orexoabpubl, LinkedIn and ir@orexo.com YouTube